In clinical practice, some oncologists consider nivolumab and ipilimumab as second-line options for metastatic NEC following platinum-based chemotherapy, particularly in cases with high PD-L1 expression or limited alternative treatments [121,122]. This evidence concerns the gene CD274 and neuroendocrine carcinoma.